All In Biotech

Drug Trial Radar · NCT06221059

Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

A Phase II Clinical Study of Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in the Treatment of Patients With Chronic Kidney Disease (Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Design)

Last checked: Nov 20, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 181 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

181

Actual

Start

Mar 2, 2024

Primary completion

Mar 5, 2025

Study completion Jun 24, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study was to evaluate the efficacy of HRS-1780 tablets or Henagliflozin Proline tablets in patients with chronic kidney disease by evaluating UACR change from baseline to Week 13

Conditions

  • Chronic Kidney Disease

Interventions

  • HRS-1780 tablet;Henagliflozin Proline tablet;HRS-1780 tablet placebo ;Henagliflozin Proline tablet placeboDrug

    Drug:HRS-1780 tablet Drug:Henagliflozin Proline tablet Drug:HRS-1780 tablet placebo Drug:Henagliflozin Proline tablet placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 13 in UACRTime frame: From Baseline to Week 13

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Hospital of Eastern Theater Command

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.